Statistical Controversies in Reporting of Clinical Trials: Part 2 of a 4-Part Series on Statistics for Clinical Trials.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the American College of Cardiology

• Publication date

  2015-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jacc.2015.10.023PMID 26670066
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

  2015cited by this paper
• Ezetimibe added to statin therapy after acute coronary syndromes

  2015cited by this paper
• Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

  2015cited by this paper
• Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes.

  2015cited by this paper
• Long-term use of ticagrelor in patients with prior myocardial infarction.

  2015cited by this paper
• Angiotensin-neprilysin inhibition versus enalapril in heart failure.

  2014cited by this paper
• Individualizing treatment choices using quantitative methods.

  2014cited by this paper
• Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

  2013cited by this paper
• Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

  2013cited by this paper
• The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial.

  2013cited by this paper
• Selecting Antiplatelet Therapy at the Time of Percutaneous Intervention for an Acute Coronary Syndrome: Weighing the Benefits and Risks of Prasugrel Versus Clopidogrel

  2013cited by this paper
• Edoxaban versus warfarin in patients with atrial fibrillation.

  2013cited by this paper
• Randomized trial of preventive angioplasty in myocardial infarction.

  2013cited by this paper
• Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

  2013cited by this paper
• The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).

  2013cited by this paper
• Rivaroxaban in patients with a recent acute coronary syndrome.

  2012cited by this paper
• Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms : Analysis of Repeat Hospitalizations

  2012cited by this paper
• Transcatheter versus surgical aortic-valve replacement in high-risk patients.

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus

  2011cited by this paper
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• Modified versus standard intention-to-treat reporting: Are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study

  2011cited by this paper
• Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.

  2010cited by this paper
• CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials

  2010cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data.

  2010cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease.

  2009cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009cited by this paper
• Analyses of cancer data from three ezetimibe trials.

  2009cited by this paper
• Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

  2009cited by this paper
• Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis

  2009cited by this paper
• CONSORT for reporting randomised trials in journal and conference abstracts.

  2008cited by this paper
• More on subgroup analyses in clinical trials.

  2008cited by this paper
• Analyses of cancer data from three ezetimibe trials.

  2008cited by this paper
• Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

  2008cited by this paper
• Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis.

  2008cited by this paper
• Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.

  2008cited by this paper
• Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events

  2008cited by this paper
• Statistics in medicine--reporting of subgroup analyses in clinical trials.

  2007cited by this paper
• Prasugrel versus clopidogrel in patients with acute coronary syndromes.

  2007cited by this paper
• Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

  2007influential reference
• Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials

  2006cited by this paper
• The charisma of subgroups and the subgroups of CHARISMA.

  2006cited by this paper
• Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

  2006cited by this paper
• Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.

  2005cited by this paper
• Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

  2005cited by this paper
• Committee for Proprietary Medicinal Products (CPMP): points to consider on adjustment for baseline covariates.

  2004cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• The role of covariates in estimating treatment effects and risk in long‐term clinical trials

  2002cited by this paper
• Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems

  2002cited by this paper
• The Effect of Bisoprolol on Perioperative Mortality and Myocardial Infarction in High-Risk Patients Undergoing Vascular Surgery

  2000cited by this paper
• Subgroup analysis and other (mis)uses of baseline data in clinical trials.

  2000cited by this paper
• Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

  2000cited by this paper
• Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine.

  2000cited by this paper
• The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.

  1999cited by this paper
• Multiplicity Considerations in the Design and Analysis of Clinical Trials

  1996cited by this paper

• Extension Reports in Clinical Trials: A Systematic Review and Consequent Guidance.

  2026cites this paper
• Optimizing duration of renin-angiotensin system inhibition after ST-elevation myocardial infarction with drug-eluting stent-percutaneous coronary intervention: Real-World Landmark Evidence from the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry.

  2026cites this paper
• Drug-coated balloon versus drug-eluting stent for treating de novo proximal left anterior descending artery lesions: Insights from the REC-CAGEFREE I trial.

  2026cites this paper
• An iterative mindset approach as an adjunct to the national diabetes prevention program: a randomized trial assessing retention, engagement and weight loss

  2026cites this paper
• A Bayesian analysis of invasive treatment strategies for elderly patients with acute coronary syndromes.

  2025cites this paper
• Association between the estimated glucose disposal rate and the occurrence of major cardiovascular events and stroke

  2025cites this paper
• Inclusion and reporting by age, sex, and ethnicity in clinical studies of high-risk medical devices approved in the European Union

  2025cites this paper
• Evidence Generation and Implementation of Transcatheter Interventions for Atrioventricular Valvular Heart Disease in Heart Failure: Current Status and Future Directions.

  2025cites this paper
• Use and misuse of composite endpoints in randomised clinical trials

  2025cites this paper
• Methodological Appraisal of Ongoing Trial of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Younger Patients: From Incentives to Guideline-Informing Evidence.

  2025cites this paper
• Association of Body Mass Index on 10-Year Outcomes in Patients Treated with Percutaneous Coronary Intervention and Drug-Eluting Stents (the DECADE Cooperation).

  2025cites this paper
• Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study

  2024cites this paper
• Ten‐year clinical outcomes after drug‐eluting stents implantation according to clinical presentation—Insights from the DECADE cooperation

  2024cites this paper
• Exploration of the regional effects of colchicine in the LoDoCo2 Trial.

  2024cites this paper
• Device-specific quality of life: Results from the ATLAS trial-Avoid Transvenous Leads in Appropriate Subjects.

  2024cites this paper
• A safety estimand for late phase clinical trials where the analysis period varies over the subjects

  2024cites this paper
• Geriatric Nutritional Risk Index at Hospital Admission or Discharge in Patients with Acute Decompensated Heart Failure

  2023cites this paper
• Do medications increase the efficacy of digital interventions for smoking cessation? Secondary results from the iCanQuit randomized trial.

  2023cites this paper
• A systematic assessment of the characteristics of randomised controlled trials cited by acute coronary syndrome clinical practice guidelines.

  2023cites this paper
• Stratified split sampling of electronic health records

  2023cites this paper
• Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization

  2023cites this paper
• Sex Differences in 10-Year Outcomes After Percutaneous Coronary Intervention With Drug-Eluting Stents: Insights From the DECADE Cooperation

  2023cites this paper
• Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease.

  2022cites this paper
• Evidence-based medicine: Friend and foe.

  2022cites this paper
• Impact of residual angina on long-term clinical outcomes after percutaneous coronary intervention or coronary artery bypass graft for complex coronary artery disease

  2022cites this paper
• Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization

  2022cites this paper
• Mortality after multivessel revascularisation involving the proximal left anterior descending artery

  2022cites this paper
• Allocated but not treated: the silent 16% – Authors' reply

  2022cites this paper
• Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

  2022cites this paper
• Responding to the humanitarian crisis of the war in Ukraine with lessons from COVID-19

  2022cites this paper
• Covariate Adjustment in Cardiovascular Randomized Controlled Trials: Its Value, Current Practice, and Need for Improvement.

  2022cites this paper
• Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial.

  2022cites this paper
• Efficacy of an acceptance and commitment therapy-based smartphone application for helping rural populations quit smoking: Results from the iCanQuit randomized trial.

  2022cites this paper
• The Aging, Community and Health Research Unit Community Partnership Program (ACHRU-CPP) for older adults with diabetes and multiple chronic conditions: study protocol for a randomized controlled trial

  2022cites this paper
• Testing a tailored weight management program for veterans with PTSD: The MOVE! + UP randomized controlled trial.

  2021cites this paper
• Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.

  2021cites this paper
• Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer

  2021cites this paper
• Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study

  2021cites this paper
• Predictors of Single Bronchodilation Treatment Response for COPD: An Observational Study with the Trace Database Cohort

  2021cites this paper
• 10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease.

  2021cites this paper
• Subgroup discovery in non‐inferiority trials

  2021cites this paper
• Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization.

  2021cites this paper
• Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease

  2021cites this paper
• Primary and Secondary Outcome Reporting in Randomized Trials: JACC State-of-the-Art Review.

  2021cites this paper
• Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease

  2021cites this paper
• Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type2 diabetes.

  2021cites this paper
• Randomized Pragmatic Trial of Pacemaker Versus Implantable Cardiac Monitor in Syncope and Bifascicular Block.

  2021cites this paper
• Interpretation of clinical trials on the cardiovascular effects of hypoglycemic drugs in people with type 2 diabetes.

  2021cites this paper
• Rabies Vaccination of 6-Week-Old Puppies Born to Immunized Mothers: A Randomized Controlled Trial in a High-Mortality Population of Owned, Free-Roaming Dogs

  2020cites this paper
• Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study.

  2020cites this paper
• with clinical after following in :

  2020cites this paper
• The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial

  2020cites this paper
• Impact of White Blood Cell Count on Clinical Outcomes in Patients Treated with Aspirin-Free Ticagrelor Monotherapy after Percutaneous Coronary Intervention: Insights from the GLOBAL LEADERS Trial.

  2020cites this paper
• Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology

  2020cites this paper
• Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial.

  2020cites this paper
• Crosstalk between Inflammation and the BBB in Stroke

  2020cites this paper
• Indispensable but deceptive evidence-based medicine.

  2020cites this paper
• Stress Reduction in the Prevention of Left Ventricular Hypertrophy: A Randomized Controlled Trial of Transcendental Meditation and Health Education in Hypertensive African Americans.

  2019cites this paper
• Evidence-based statistical analysis and methods in biomedical research (SAMBR) checklists according to design features.

  2019cites this paper
• Improving the reporting quality of intervention trials addressing the inter-individual variability in response to the consumption of plant bioactives: quality index and recommendations

  2019cites this paper
• Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.

  2019cites this paper
• A Pilot Randomized Controlled Trial of a Web-Based Growth Mindset Intervention to Enhance the Effectiveness of a Smartphone App for Smoking Cessation

  2019cites this paper
• Critical appraisal of clinical trials in oncology — part II

  2019cites this paper
• Alirocumab, Decreased Mortality, Nominal Significance, P Values, Bayesian Statistics, and the Duplicity of Multiplicity.

  2019cites this paper
• The connecting adolescents to reduce relapse (CARR) trial: study protocol for a randomized controlled trial comparing the efficacy of Groups 4 Health and cognitive behaviour therapy in young people

  2019cites this paper
• Adherence to World Glaucoma Association Guidelines for Surgical Trials in the Era of Microinvasive Glaucoma Surgeries.

  2019cites this paper
• Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial.

  2019influential citation
• Qing-Xin-Jie-Yu Granule for patients with stable coronary artery disease (QUEST Trial): A multicenter, double-blinded, randomized trial.

  2019cites this paper
• hyPertenSive african americanS

  2019cites this paper
• Does the use of incretin‐based medications increase the risk of cancer in patients with type‐2 diabetes mellitus?

  2019cites this paper
• Evidence-based and tailored medication in type 2 diabetes: a pathway learned from clinical trials

  2019cites this paper
• Lessons from Randomised Clinical Trials for Triiodothyronine Treatment of Hypothyroidism: Have They Achieved Their Objectives?

  2018cites this paper
• Continued uncertainty regarding treatment of patent ductus arteriosus in premature infants and the role of clinical trials.

  2018cites this paper
• Critical appraisal of cardiology guidelines on revascularisation: clinical practice

  2018cites this paper
• Is There Really a Benefit to Net Clinical Benefit in Testing Antithrombotics?

  2018cites this paper
• Why Do I Need a Will Anyway? Assessing the Impact of a Public Legal Education Intervention Embedded in a Longitudinal Survey

  2018cites this paper
• Medical Biostatistics: Basic Concepts

  2018cites this paper
• A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components

  2018cites this paper
• Statistical considerations in reporting cardiovascular research.

  2018cites this paper
• Community Program Improves Quality of Life and Self‐Management in Older Adults with Diabetes Mellitus and Comorbidity

  2017cites this paper
• Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach?

  2017cites this paper
• Upright versus lying down position in second stage of labour in nulliparous women with low dose epidural: BUMPES randomised controlled trial

  2017cites this paper
• Clinical Trials in Veterinary Medicine: A New Era Brings New Challenges

  2017cites this paper
• An introduction to multiplicity issues in clinical trials: the what, why, when and how.

  2016cites this paper
• Saxagliptin and risk of heart failure hospitalization: Concern or miscalculation?

  2016cites this paper
• Approach to mitigate challenges in Clinical Trial Supply Management

  2016cites this paper
• Implications of Coronary Artery Calcium Testing Among Statin Candidates According to American College of Cardiology / American Heart Association Cholesterol Management Guidelines : MESA ( Multi-Ethnic Study of Atherosclerosis )

  2016cites this paper
• The Primary Outcome Fails - What Next?

  2016cites this paper
• Editor-in-Chief's Top Picks From 2015: Part Two.

  2016cites this paper
• Unraveling the Complexities of Statistical Presentation: Why it Is Important.

  2015cites this paper
• compu-The top of the evidence pyramid

  year unknowncites this paper